Scilex holding sells $200m in Semnur Pharmaceuticals shares

Scilex Holding Co (NASDAQ:SMNR) and Scilex, Inc., both ten percent owners of Semnur Pharmaceuticals, sold a combined 12,499,999 shares of Semnur common stock for $200 million at $16.00 per share. This significant divestment, dated September 23, 2025, was executed with Biconomy PTE.LTD. and notably settled in Bitcoin. Separately, Scilex Holding Co (SMNR) itself, currently trading at $12.05 with a $31.08 million market cap, has demonstrated strong market momentum with a 66% return over the past year, often showing price movements divergent from broader market trends.

Analysis

Scilex Holding Co (SMNR) and an affiliate have entered into an agreement to divest a combined 12.5 million shares of Semnur Pharmaceuticals stock for a total of $200 million, priced at $16.00 per share. The transaction, dated for September 23, 2025, implies a forward sale agreement and is notable for its unconventional settlement method in Bitcoin, exposing the company to cryptocurrency market volatility. This event provides a significant future liquidity injection for Scilex, which will retain a substantial holding of over 181 million Semnur shares post-sale. Despite this large insider sale, SMNR's stock has shown strong performance with a 66% return over the past year, although it currently trades at $12.05, near the bottom of its 52-week range. The credibility of the reporting is questionable, as evidenced by a completely unrelated headline about pharmaceutical tariffs and conflicting ticker symbols (SMNR and SCLX), suggesting the underlying facts require independent verification.

Key Decisions for Investors

• Investors should verify the details of this significant, future-dated insider transaction through official SEC filings before taking any action, given the questionable reliability of the source article.
• The $16.00 per share sale price for the Semnur stake could be used as a valuation benchmark for Scilex's remaining assets, but this potential upside must be weighed against the risks of the large insider sale and the unconventional Bitcoin settlement.
• Monitor the company's risk exposure related to the Bitcoin payment mechanism and the execution of the forward sale in 2025, as these factors introduce significant volatility not typical for a pharmaceutical holding entity.